~~<i id='3BD7DD537B'><strike id='3BD7DD537B'><tt id='3BD7DD537B'><pre id='3BD7DD537B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：leisure time 2025-10-01 15:30:25 - browse：34512

Three sales executives, all of them women, have filed suit against Grail, a cancer diagnostics company, alleging that they were harassed, that the company failed to take corrective action, and that it retaliated by removing them from consideration for promotions.

The suits, which were filed earlier this week, are complicated by the fact that Grail was purchased by Illumina, the largest DNA sequencing firm, for $8 billion in 2021 — yet Illumina has left Grail to operate as a separate company. Illumina is named in the suit.

All three plaintiffs are being represented by the Vora Law Firm, based in Santa Monica, Calif.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

focus

knowledge

entertainment

focus

hotspot

entertainment

PauloAmorim/VWPicsviaAPImagesLONDON—Thisweek,EuropeanregulatorsareconsideringanappealfromAmylyxPharm

WSS

Dana Farber says 6 studies to be retracted and 31 corrected

To bolster infectious disease surveillance, genomics powerhouses team up

Mass General, Mayo Clinic look to monetize custom

Researchers CRISPR chickens in bid to protect them from bird flu

Bernie Sanders bashes nonprofit hospitals over their tax breaks

What the Wegovy shortage looks like for doctors — and for patients

leisure time

fashion

focus

Apple is now the first public company to be valued at $3 trillion

Better Therapeutics data on benefit with GLP

Apple is now the first public company to be valued at $3 trillion

Printout prescription drug information shouldn’t go digital

DIEP, the 'gold standard' of breast reconstruction, is under threat

Mass General, Mayo Clinic look to monetize custom

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Maisha Meds is a PBM, but don't call it that

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Humana CEO Bruce Broussard to step down in 2024

knowledge

To bolster infectious disease surveillance, genomics powerhouses team up

What's changing in Medicare's open enrollment this year?

Head of FDA's diagnostics center, who led through Covid, retires

Medicare to cover more brain scans related to Alzheimer’s drugs

There’s no way to know how good AI health technologies are

Life sciences deals on track to hit lowest point since 2017

entertainment

focus

hotspot

entertainment